Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Intellego: Expert Advice for Choosing and Using UV-C Disinfection Systems for Your Facility

“Deploying UV-C technology requires meeting facility needs and ensuring they know how to use it and validate it that it’s working properly.” Disinfection is at the forefront of everyone’s mind in a pandemic. As a result, most facilities need a portfolio of tools to support this, with UV-C being one of those. But how can…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Intellego: Expert Advice for Choosing and Using UV-C Disinfection Systems for Your Facility

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

“Deploying UV-C technology requires meeting facility needs and ensuring they know how to use it and validate it that it’s working properly.”

Disinfection is at the forefront of everyone’s mind in a pandemic. As a result, most facilities need a portfolio of tools to support this, with UV-C being one of those. But how can organizations implement it and ensure it’s working? In this discussion, host Daniel Litwin spoke to two subject matter experts, Wendy Brady-Walling, Director of Global Marketing, Intellego Technologies, and Christine Gallo, CEO, Gallo Medical Company and IP Program.

Gallo, already in the medical industry, became a bigger advocate for infection prevention and disinfection after a family member’s health battle. “I realized we have to do better, and that’s what led me to add UV-C to the toolbox to help with this,” she said.

Gallo’s objective now is to partner with facilities to help them find funding to acquire and deploy UV-C disinfection systems and ensure it’s working by using UV-C dosimeters, which provide visual validation of disinfection. She noted that dosimeters are included in the purchase of the UV-C equipment and that her team trains staff on how to use them.

Brady-Walling discussed the many delivery systems of UV-C, from mobile towers to ceiling mounts to autonomous robots. “Pre-COVID, UV-C disinfection systems were considered ‘nice to have.’ Now they’re a ‘need to have.’ That’s why we’re focused on educating industries about its availability, safety, efficacy, and efficiency.”

The pandemic also meant using UV-C in new spaces, including restaurants, airports, gyms, and office buildings. In the healthcare setting, UV-C was in use in operating rooms. “They are using it in patient rooms prior to staff cleaning, so it’s safer for them. We just deployed it at a cancer center.”

Brady-Walling added, “They love the technology and the visual evidence from the dosimeter that it was a successful disinfection.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512